Showing 1 - 10 of 687,169
Who gains from more information on the quality of pharmaceutical drugs? Are there incentives for voluntary post-approval clinical trials among pharmaceutical companies? Contrary to popular belief, this paper shows that it is not in the consumer interest that clinical evidence establishing the...
Persistent link: https://www.econbiz.de/10003373751
Who gains from more information on the quality of pharmaceutical drugs? Are there incentives for voluntary post-approval clinical trials among pharmaceutical companies? Contrary to popular belief, this paper shows that it is not in the consumer interest that clinical evidence establishing the...
Persistent link: https://www.econbiz.de/10005423798
The year of 1997 witnessed an important change in direct-to-consumer (DTC) advertising of prescription drugs. For the first time, the Food and Drug Administration (FDA) permitted brand-specific DTC ads on TV without a "brief summary" of comprehensive risk information. This led to a three-fold...
Persistent link: https://www.econbiz.de/10014031773
In "Marketing Information: A Competitive Analysis,'' Sarvary and Parker (1997) (S&P) [Marketing Science, 16(1): 24-38] argue that, a reduction in the price of one information product can lead to an increase in demand for another information product -- information products can be gross...
Persistent link: https://www.econbiz.de/10013023359
In "Marketing Information: A Competitive Analysis,'' Sarvary and Parker (1997) (S&P) [Marketing Science, 16(1): 24-38] argue that in part of the parameter space that they considered, a reduction in the price of one information product can lead to an increase in demand for another information...
Persistent link: https://www.econbiz.de/10013225884
The prevalence of misinformation has spurred various interested parties--regulators, the media, and competing firms--to debunk false claims in the marketplace. This paper studies whether such debunking messages provided by these parties can impact consumer purchase behavior. If so, does...
Persistent link: https://www.econbiz.de/10014088138
Private firms often withhold information or contest scientific knowledge when public revelation could lead to costly regulations or liability. This concealment leads to negative externalities and public harm. But what if private firms' superior knowledge and self-interest could be harnessed to...
Persistent link: https://www.econbiz.de/10012927870
Among non-specialists, the estimates of the HIV/AIDS transmission rate are generally upwardly biased. This overestimation may be perceived as a godsend, as it increases the incentives to have protected sexual relationships. However, a pernicious effect may counterbalance this positive effect....
Persistent link: https://www.econbiz.de/10013104279
In this paper, I study the effect of parallel trade (cross border resale of goods without the authorization of the manufacturer) on pharmaceutical regulation in a North-South framework with a firm's endogenous decision to export to the South. Governments in both countries may limit prices...
Persistent link: https://www.econbiz.de/10011986314
This paper studies the effect of two regulatory instruments - a price cap and a reference price system - a mandatory substitution rule, and the combination of both on generic competition in a Salop-type model with an off-patent brand-name drug and n differentiated generic versions. The price cap...
Persistent link: https://www.econbiz.de/10010510801